(S)-Metoprolol

(S)-Metoprolol

SCHEMBL121589

COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of (S)-Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 4/20 1.00
ADRB2 P07550 3/20 1.00
CYP2D6 P10635 2/20 1.00
NR3C1 P04150 1/20 1.00
ADRA1A P35348 1/20 1.00
CYP2J2 P51589 1/20 1.00
PDE4D Q08499 1/20 1.00
NPY1R P25929 1/20 0.84
NPY2R P49146 1/20 0.84
PMP22 Q01453 1/20 0.84
NPSR1 Q6W5P4 1/20 0.84
TDP1 Q9NUW8 1/20 0.84
LMNA P02545 2/20 0.68
MEN1 O00255 1/20 0.68
CYP1A2 P05177 1/20 0.68
CYP2C9 P11712 1/20 0.68
KMT2A Q03164 1/20 0.68
GAA P10253 1/20 0.67
BLM P54132 1/20 0.67
TMEM97 Q5BJF2 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metoprolol SCHEMBL1561123 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL4093 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
(R)-Metoprolol SCHEMBL40918 1.00 ADRB1 (1.00) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL28445291 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
(S)-Metoprolol SCHEMBL2638035 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL6126034 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
(S)-Metoprolol SCHEMBL6728301 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL2638034 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL27911917 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A
Metoprolol SCHEMBL613509 0.99 ADRB1 (0.97) ADRB1ADRB2CYP2D6NR3C1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7398 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
EP-4731194-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP Technologies, Inc. (US) 2026-04-29 EP claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4694856-A1 CALENDAR MEDICATION BLISTER PACK, METHOD OF USING THEREOF AND ELECTRONIC SYSTEM OF MANAGEMENT OF INTERACTION WITH CALENDAR MEDICATION BLISTER PACK Mili Healthcare Trade Fzco (AE) 2026-02-18 EP claimed
EP-4687805-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP Technologies, Inc. (US) 2026-02-11 EP claimed
US-20260027008-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP TECHNOLOGIES, INC. 2026-01-29 US claimed
US-12508321-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-12-30 US claimed
WO-2025264260-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP TECHNOLOGIES, INC. (US) 2025-12-26 WO claimed
EP-0193228-B1 PROCESS FOR PRODUCING OF 4-(2-METHOXYETHYL)-PHENYLGLYCIDYL ETHER AND/OR METOPROLOL GIST-BROCADES N.V. (NL) 1989-11-02 EP claimed
EP-0036138-B2 Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide MERCK & CO. INC. (US) 1989-10-25 EP claimed
EP-0130119-B1 (ACYLOXYALKOXY) CARBONYL DERIVATIVES AS BIOREVERSIBLE PRODRUG MOIETIES FOR PRIMARY AND SECONDARY AMINE FUNCTIONS IN DRUGS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES MERCK & CO. INC. (US) 1988-11-09 EP claimed
EP-0271438-A2 Oral osmotic system for metoprolol having a specific composition CIBA-GEIGY AG (CH) 1988-06-15 EP claimed
EP-0069385-B1 USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS MERCK & CO. INC. (US) 1987-10-14 EP claimed
EP-0229947-A1 Novel crystalline salts of aryloxy-propanolamines, their preparation and their use RORER INTERNATIONAL (OVERSEAS) INC. (US) 1987-07-29 EP claimed
EP-0073819-B1 NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR The University of Kentucky Research Foundation (US) 1987-05-27 EP claimed
EP-0193228-A1 Process for producing of 4-(2-methoxyethyl)-phenylglycidyl ether and/or metoprolol GIST-BROCADES N.V. (NL) 1986-09-03 EP claimed
EP-0036138-B1 COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE MERCK & CO. INC. (US) 1985-08-28 EP claimed
EP-0152379-A2 Process for preparing pharmaceutical compositions containing unilamellar liposomes CIBA-GEIGY AG (CH) 1985-08-21 EP claimed